Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.03.025
- Author:
Li-Ping DOU
1
;
Yu JING
;
Quan-Shun WANG
;
Jun-Hui MEI
;
Li YU
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Azacitidine;
administration & dosage;
analogs & derivatives;
therapeutic use;
Female;
Haploidy;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
therapy;
Lymphocyte Transfusion;
Lymphocytes;
Male;
Middle Aged;
Myelodysplastic Syndromes;
drug therapy;
therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2013;21(3):662-666
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to observe the clinical efficacy and adverse effects of decitabine plus improved CAG chemotherapy and haploid-identical donor peripheral lymphocyte infusion regimen on elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Five elderly patients with MDS and AML were treated with decitabine plus improved CAG chemotherapy and donor peripheral lymphocyte infusion regimen. Examinations on liver and renal function, electrocardiogram and bone marrow analysis were performed before and after treatment, and adverse effects were observed. The results indicated that after a course of treatment by decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen, the total effective rate was 100%, and 4 patients (80%) achieved complete remission, 1 patient achieved partial remission. The dominant clinical adverse effect was bone marrow depression, the median time of neutrophil>0.5×10(9)/L and platelet>20×10(9)/L was 15 d and 16 d respectively for patients without previous MDS. It is concluded that decitabine plus improved CAG chemotherapy and haploid-identical donor peripheral lymphocyte infusion regimen may be effective with less adverse effects for elderly primary AML and high risk MDS patients, it is a promising therapeutic methods and worthy to deeply study.
